Form 4: Gilead Sciences CEO Sells Shares Under 10b5-1 Plan
Statement of Changes in Beneficial Ownership
Gilead Sciences Chairman & CEO Daniel O'Day reported the sale of company stock under a pre-arranged trading plan.
Summary
- Daniel Patrick O'Day, Chairman & CEO of Gilead Sciences, Inc., reported transactions involving the sale of common stock.
- These transactions were executed under a Rule 10b5-1 trading plan adopted on February 25, 2026.
- A total of 11,900 shares were sold at prices ranging from $125.59 to $126.55, resulting in 610,233 shares beneficially owned.
- An additional 3,100 shares were sold at prices ranging from $126.595 to $127.44, leaving 607,133 shares beneficially owned.
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a neutral to slightly negative filing due to the CEO selling shares, although the use of a 10b5-1 plan mitigates some of the negative sentiment.
Negatives
- Company insider, the CEO, sold a significant number of shares.
Future Outlook
The filing does not contain forward-looking statements or guidance.
Industry Context
StockSavvy.ai notes that insider sales, particularly by C-suite executives, can sometimes be interpreted negatively by the market, even when conducted under a pre-established 10b5-1 plan, as it signals a reduction in direct ownership by leadership.
Stakeholder Impact
- Shareholders may view the CEO's stock sale with caution, despite the 10b5-1 plan, potentially impacting short-term investor sentiment.
Key Dates
| Date | Description |
|---|---|
| 02/25/2026 | Date Rule 10b5-1 trading plan was adopted. |
| 07/01/2026 | Earliest transaction date reported. |
| 07/02/2026 | Date of signature for the filing. |
Recommendation
holdThe sale of shares by the CEO under a 10b5-1 plan is a routine event for insiders to diversify or manage personal finances. While it can cause short-term market jitters, it does not inherently signal a negative outlook for the company's fundamentals. Therefore, a 'hold' recommendation is appropriate pending further company news or performance indicators.
Keywords
Gilead Sciences, GILD, Form 4, Insider Trading, Stock Sale, Rule 10b5-1, CEO, Daniel O'Day
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.